Athena Countouriotis

Athena M.
Countouriotis is the founder of Avenzo Therapeutics, Inc. Current positions include Chairman at Recludix Pharma, Inc. since 2022, Chairman at Capstan Therapeutics, Inc. since 2022, Independent Director at BioMarin Pharmaceutical, Inc. since 2023, Independent Director at Iovance Biotherapeutics, Inc. since 2019, Director at NuMedii, Inc. since 2018, Independent Director at Passage Bio, Inc. since 2020, and Director at Leal Therapeutics, Inc. Former roles include President, Chief Executive Officer & Director at Turning Point Therapeutics, Inc. from 2021 to 2022, Director-Oncology Global Clinical Research at Bristol Myers Squibb Co., Associate Medical Director at CTI BioPharma Corp., Independent Director at Cardiff Oncology, Inc. from 2017 to 2020, Chief Medical Officer & Senior Vice President at Halozyme Therapeutics, Inc. from 2015 to 2017, Chief Medical Officer at Ambit Biosciences Corp.
from 2012 to 2014, and Chief Medical Officer & Senior Vice President at Adverum Biotechnologies, Inc. from 2017 to 2018.
Education includes undergraduate studies at the University of California, Los Angeles and a doctorate from Tufts University School of Medicine.